A Study To Assess The Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19

NCT05713318 PHASE2 COMPLETED

This is a randomized, double-blind, placebo-controlled Phase 2 study in participants over the age of 18 years with mild COVID-19. The main purpose of this study is to evaluate the effect on viral load clearance and clinical recovery, and safety of HH-120 nasal spray in participants over the age of 18 years with mild COVID-19 (according to the FDA definition, 2021).

Details

Lead sponsor	Huahui Health
Phase	PHASE2
Status	COMPLETED
Enrolment	200
Start date	Wed Jan 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jun 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• COVID-19

Interventions

• HH-120 nasal spray
• HH-120 nasal spray
• Placebo Comparator
• Placebo Comparator

Countries

China